Cencora, Inc. (NYSE:COR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $393.0833.
Several equities research analysts have recently weighed in on COR shares. JPMorgan Chase & Co. upped their target price on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Mizuho upped their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a report on Thursday. Finally, TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th.
Check Out Our Latest Report on Cencora
Insider Activity at Cencora
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of COR. Atlantic Edge Private Wealth Management LLC raised its stake in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. IAG Wealth Partners LLC acquired a new stake in shares of Cencora during the 3rd quarter valued at about $30,000. Vermillion & White Wealth Management Group LLC increased its stake in Cencora by 69.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares during the period. Cloud Capital Management LLC acquired a new position in Cencora in the third quarter worth about $31,000. Finally, Caitlin John LLC acquired a new position in Cencora in the third quarter worth about $31,000. Institutional investors own 97.52% of the company’s stock.
Cencora Trading Up 0.2%
Shares of Cencora stock opened at $353.07 on Friday. Cencora has a 1 year low of $237.71 and a 1 year high of $377.54. The company’s fifty day simple moving average is $348.49 and its 200-day simple moving average is $321.90. The company has a market cap of $68.49 billion, a price-to-earnings ratio of 44.41, a PEG ratio of 1.68 and a beta of 0.66. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.
Cencora (NYSE:COR – Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the company earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts expect that Cencora will post 15.37 EPS for the current year.
Cencora Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio is 30.19%.
Cencora Company Profile
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Articles
- Five stocks we like better than Cencora
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- The $100 Trillion AI Story No One Is Telling You
- Buy This Stock at 9:30 AM on MONDAY!
- A U.S. “birthright” claim worth trillions – activated quietly
- If You Keep Cash In A U.S. Bank Account… Read This NOW
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
